首页> 美国卫生研究院文献>BMC Cardiovascular Disorders >The REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical decision rule NT-proBNP or their combination in the diagnosis of heart failure in primary care. Rationale and design
【2h】

The REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical decision rule NT-proBNP or their combination in the diagnosis of heart failure in primary care. Rationale and design

机译:REFER(EchocaRdiogram的参考)方案:对临床决策规则NT-proBNP或其组合进行前瞻性验证以诊断初级保健中的心力衰竭。原理和设计

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundHeart failure is a major cause of mortality and morbidity. As mortality rates are high, it is important that patients seen by general practitioners with symptoms suggestive of heart failure are identified quickly and treated appropriately. Identifying patients with heart failure or deciding which patients need further tests is a challenge. All patients with suspected heart failure should be diagnosed using objective tests such as echocardiography, but it is expensive, often delayed, and limited by the significant skill shortage of trained echocardiographers. Alternative approaches for diagnosing heart failure are currently limited. Clinical decision tools that combine clinical signs, symptoms or patient characteristics are designed to be used to support clinical decision-making and validated according to strict methodological procedures. The REFER Study aims to determine the accuracy and cost-effectiveness of our previously derived novel, simple clinical decision rule, a natriuretic peptide assay, or their combination, in the triage for referral for echocardiography of symptomatic adult patients who present in general practice with symptoms suggestive of heart failure.
机译:背景心力衰竭是死亡和发病的主要原因。由于死亡率很高,因此必须快速识别并适当治疗普通医生所见的具有心力衰竭症状的患者。识别心力衰竭患者或确定哪些患者需要进一步检查是一个挑战。所有疑似心力衰竭的患者均应使用客观检查(例如超声心动图)进行诊断,但价格昂贵,经常被延误并且受训练有素的超声心动图师技能严重不足的限制。当前,用于诊断心力衰竭的替代方法受到限制。结合临床体征,症状或患者特征的临床决策工具旨在支持临床决策并根据严格的方法学程序进行验证。 REFER研究旨在确定我们先前得出的新颖,简单的临床决策规则,利钠肽测定法或它们的组合的准确性和成本效益,将其转诊为有症状的有症状的成年患者进行超声心动图检查提示心力衰竭。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号